drugset / Trial / NCT02066662

Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

NCT02066662

Phase 4 Completed 192 enrolled RWTH Aachen University Bayer · collab
RandomizedParallel-groupSingle-blindBasic science

Summary

The following trial hypothesis will be proved: In patients with atrial fibrillation and/ or pulmonary embolism standard anticoagulant treatment with coumadin/phenprocoumon is associated with accelerated coronary or valvular calcification as assessed by cardiac computed tomography compared to the new anticoagulant therapy with rivaroxaban.

Timeline

Start
2013-07
Primary completion
2020-03
Completion
2020-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Phenprocoumon Small molecule Oral
Subject Rivaroxaban Other / unclassified 15 mg Oral
Subject Rivaroxaban Other / unclassified 20 mg Oral

Indications